FindTrial
Sign In

A Clinical Study on the Efficacy of Acupuncture Point Subcutaneous Implantation Therapy (Nourishing Kidney and Harmonizing Blood) for Patients with Kidney Deficiency and Blood Stasis Type Ovarian Reserve Function Decline in In Vitro Fertilization-Embryo Transfer Outcomes

A Clinical Study on the Effect of 'Nourishing Kidney and Harmonizing Blood' Acupuncture Point Subcutaneous Suture Therapy on In Vitro Fertilization-Embryo Transfer Outcomes in Patients with Decreased Ovarian Reserve Function Due to Kidney Deficiency and Blood Stasis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000887
Enrollment
Unknown
Registered
2026-04-03
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian reserve function decline

Interventions

Experimental Group:Acupuncture point embedding+Routine Femoston therapy and IVF-ET
Control Group:Routine Femoston therapy and IVF-ET

Sponsors

Shenzhen Maternal and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 39 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for decline in ovarian reserve function of the type of kidney deficiency and blood stasis; (2) Female, aged 20 years = age < 40 years; (3) Has fertility needs and plans to undergo IVF-ET; (4) Voluntarily participates in the trial and signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Combined conditions affecting conception (any one of the following): congenital abnormalities of reproductive organ development, untreated endometrial polyps, untreated intrauterine infection, untreated tubal hydrosalpinx, thin endometrial lining, uterine fibroids, endometriosis, or other organic diseases; (2) Medical factors (e.g., pelvic surgery, chemotherapy/radiotherapy, uterine artery embolization, medications such as hormones, immunosuppressants, etc.) causing decreased ovarian reserve function; (3) Use of hormonal medications (e.g., contraceptives, glucocorticoids) within the past three months (excluding those undergoing in vitro fertilization-embryo transfer); (4) Severe cardiovascular, hepatic, renal, malignant tumor, hematologic, or psychiatric diseases; (5) Local skin infection, ulcers, or tendency to form keloids; (6) Allergy to acupuncture point embedding or other adverse reactions; (7) Cancellation of IVF-ET treatment during the study period; (8) Refusal to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Clinical Pregnancy Rate;—

Secondary

MeasureTime frame
anti-Müllerian hormone;estradiol;Follicle-Stimulating Hormone;endometrial thickness;Antral Follicle Coun;Resistance Index;High-Quality Embryo Rate; AI 3/1000 Number of oocytes retrieved;Traditional Chinese Medicine Syndrome Scoring;—

Countries

China

Contacts

Public ContactJiaman Wu

henzhen Maternity and Child Healthcare Hospital

wujiaman202@163.com15817470407

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026